Elizabeth Schneider: Revolutionary Drug Shows Promise for Primary Ovarian Insufficiency
Elizabeth Schneider, Staff Product Marketing Manager at Illumina, shared a post on LinkedIn:
“Primary ovarian insufficiency (POI), in which the ovaries don’t mature and release eggs properly, affects about 3% of women under age 40 and typically causes infertility. But a drug already approved to treat kidney disease may one day help some of these people get pregnant, a research team reports today in Science.
In studies of mouse ovarian tissue and live mice, the drug, called finerenone, kick-started the growth of tiny egg-containing sacs, or follicles—a process that’s often defunct in people with POI. In a small clinical trial, people with POI who were given the drug went on to produce mature eggs that could be harvested, and some of the eggs were then successfully fertilized in the lab.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Jun 6, 2026, 07:48Did You Know You Can Actively Contribute to ESHRE Guidelines? – ESHRE
-
Jun 6, 2026, 07:44Subfertility and Congenital Anomalies – Fertility and Sterility
-
Jun 6, 2026, 07:38France, Belgium, UK, Spain, and Quebec Compared in New ART Funding Analysis – RBMO
-
Jun 6, 2026, 07:25New ESHRE Podcast Explores Impact of Uterine Artery Occlusion on Ovarian Reserve – ESHRE
-
Jun 6, 2026, 07:22Khalil Faaed: Is the Zygote Already Revealing Its Future?
-
Jun 6, 2026, 07:16Did You Know Your Ovaries Operate in Waves? – Fertility Plus
-
Jun 6, 2026, 07:12Kazem Nouri: Women’s Health Day Highlights Fertility Preservation, Family Planning and Endometriosis
-
Jun 6, 2026, 07:10PCOS Is Now PMOS, A New Name for a Complex Condition! – Gedeon Richter France
-
Jun 6, 2026, 07:06Research Highlights Increased PAS Risk in Programmed-Cycle Frozen Embryo Transfers – RBMO